Market Intelligence, Clinical Progress, and High-Purity Reagents for Extracellular Matrix & Oncology Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FREM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FREM1 Recombinant Fragment Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View FREM1 Products |
| Gene Delivery | FREM1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and expression validation. |
View FREM1 Products |
| Benchmark Ab | Anti-FREM1 Recombinant Antibody Recombinant positive control for assay validation. |
View FREM1 Products |
| Validator | FREM1 siRNA Set For knockdown verification in functional assays. |
View FREM1 Products |
| Related Target A | FRAS1 Partner in the FRAS1/FREM1/GRIP1 extracellular matrix complex; critical for epithelial-mesenchymal cohesion. |
View FRAS1 Products |
| Related Target B | GRIP1 Intracellular adaptor protein that anchors the FRAS1/FREM1 complex to the cytoskeleton. |
View GRIP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Molecular Weight & Complex Folding (Large CSPG repeats) | Truncated functional domain design expressed in HEK293 to ensure native post-translational modifications and solubility. |
| Cross-species Reactivity Verification | Human and Mouse ortholog proteins strictly verified by Mass Spectrometry to support preclinical translation. |
| Lack of Validated Controls | Recombinant Benchmark Antibodies and validated siRNA sets included for target specificity verification. |
| False Positives in ECM Binding Assays | Endotoxin-controlled (<1.0 EU/μg) and high-purity (>95%) protein batches to eliminate non-specific background. |
Live FREM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic exploration of FREM1 (FRAS1-related extracellular matrix protein 1) is gaining traction as researchers uncover its dual role in rare developmental disorders (such as Fraser syndrome) and oncology. In cancer, FREM1 modulates the tumor microenvironment (TME) and immune cell infiltration, particularly in breast and colorectal cancers. The next wave of R&D is focusing on targeting FREM1-associated extracellular matrix pathways to overcome immune evasion and enhance the efficacy of immune checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Academic & Biotech Consortia | Solid Tumors (Breast, Colorectal) | Binding Affinity & Epitope Mapping (Requires high-purity recombinant FREM1 domains) |
| Gene Therapy / mRNA | Rare Disease R&D Labs | Fraser Syndrome, Congenital Defects | Expression Validation & Rescue Assays (Requires FREM1 Lentivirus for stable cell lines) |
| Diagnostic Biomarkers | In Vitro Diagnostic Developers | Oncology Prognosis, Prenatal Screening | High-specificity detection (Requires sequence-verified antigen and positive controls) |